Group 1 - The Hong Kong stock market's pharmaceutical sector is experiencing multiple catalysts in early 2026, including significant BD transactions in AI healthcare, positive news regarding brain-computer interfaces overseas, and the implementation of commercial insurance for innovative drugs [1] - The Hang Seng Biotechnology Index has seen a strong increase, with a year-to-date rise exceeding 13%, leading the key indices in the Hong Kong stock market [1] - The Hong Kong Stock Exchange launched Hang Seng Biotechnology Index futures in November 2025, enhancing its expanding ecosystem of derivative products and providing investors with precise risk management tools [1] Group 2 - The Hang Seng Biotechnology Index is the only index in the Hong Kong stock market with index futures for the pharmaceutical and healthcare sectors [1] - Among the ETFs tracking the Hang Seng Biotechnology Index, the Hang Seng Healthcare ETF (159892) ranks first in scale, exceeding 7 billion, and offers good liquidity for investors looking to invest in the biotechnology sector [1]
“脑机接口+AI医疗+创新药”多重催化！恒生生物科技2026年涨幅超13%
Sou Hu Cai Jing·2026-01-12 03:36